drugset / Trial / NCT00600353
Multi-day Doses in Prevention of Nausea and Emesis
NaSingle-groupOpen-labelSupportive care
Summary
To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma undergoing autologous HSCT utilizing the Multinational Association for Supportive Care in Cancer (MASCC) Antiemesis Tool (MAT).
Timeline
- Start
- 2007-10
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | 80 mg | Oral |
| Subject | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |
| Background | Dexamethasone | Small molecule | 4 mg | Intravenous |